Radalbuvir
Radalbuvir is an experimental antiviral drug for the treatment of hepatitis C virus infection developed by Gilead Sciences. Radalbuvir acts as an NS5B inhibitor. It is currently in clinical trials. It targets NS5B polymerase.
Radalbuvir is an experimental antiviral drug for the treatment of hepatitis C virus infection developed by Gilead Sciences. Radalbuvir acts as an NS5B inhibitor. It is currently in clinical trials. It targets NS5B polymerase.